1 completed, 1 withdrawn. 1 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Anjali Sharathkumar: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia Romiplostim, Immunosuppressive therapy (IST) - Aplastic Anemia | Phase 2 | Withdrawn | Anjali Sharathkumar | 2025-04-10 | 2026-10-16 | |
| TPO-Mimetic Use in Children for Hematopoietic Failure Romiplostim - Bone Marrow Failure Disorders, Aplastic Anemia | Early Phase 1 | Completed | Anjali Sharathkumar | 15 | 2020-08-18 | 2024-07-30 |
Anemia, Aplastic (2) · Bone Marrow Failure Disorders (1) · Myelodysplastic Syndromes (1) · Thrombocytopenia (1)
romiplostim (2) · Immunosuppression Therapy (1)
United States (2)